Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
Black Diamond Therapeutics (Nasdaq: BDTX), a clinical-stage oncology company specializing in MasterKey therapies for cancer treatment, has announced its upcoming participation in two major investor conferences.
The company's President and CEO, Mark Velleca, M.D., Ph.D., will present at the following events:
- 24th Annual Needham Virtual Healthcare Conference - April 7, 2025, at 3:00 PM ET
- Stifel 2025 Virtual Targeted Oncology Forum - April 8, 2025, at 1:00 PM ET
Both presentations will be accessible via webcast on the investor relations section of Black Diamond Therapeutics' website, with replays available for 90 days.
Black Diamond Therapeutics (Nasdaq: BDTX), un'azienda oncologica in fase clinica specializzata in terapie MasterKey per il trattamento del cancro, ha annunciato la sua prossima partecipazione a due importanti conferenze per investitori.
Il Presidente e CEO dell'azienda, Mark Velleca, M.D., Ph.D., presenterà ai seguenti eventi:
- 24a Conferenza Sanitaria Virtuale di Needham - 7 aprile 2025, alle 15:00 ET
- Forum Virtuale di Oncologia Mirata Stifel 2025 - 8 aprile 2025, alle 13:00 ET
Entrambe le presentazioni saranno accessibili tramite webcast nella sezione relazioni con gli investitori del sito web di Black Diamond Therapeutics, con repliche disponibili per 90 giorni.
Black Diamond Therapeutics (Nasdaq: BDTX), una empresa oncológica en etapa clínica especializada en terapias MasterKey para el tratamiento del cáncer, ha anunciado su próxima participación en dos importantes conferencias para inversores.
El Presidente y CEO de la empresa, Mark Velleca, M.D., Ph.D., presentará en los siguientes eventos:
- 24ª Conferencia Virtual de Atención Médica de Needham - 7 de abril de 2025, a las 3:00 PM ET
- Foro Virtual de Oncología Dirigida Stifel 2025 - 8 de abril de 2025, a la 1:00 PM ET
Ambas presentaciones estarán disponibles a través de webcast en la sección de relaciones con inversores del sitio web de Black Diamond Therapeutics, con repeticiones disponibles durante 90 días.
블랙 다이아몬드 테라퓨틱스 (Nasdaq: BDTX), 암 치료를 위한 마스터키 치료법을 전문으로 하는 임상 단계의 종양학 회사가 두 개의 주요 투자자 회의에 참여할 예정이라고 발표했습니다.
회사의 회장 겸 CEO인 Mark Velleca, M.D., Ph.D.가 다음 행사에서 발표할 예정입니다:
- 제24회 니드햄 가상 의료 회의 - 2025년 4월 7일, 오후 3시 ET
- 스티펠 2025 가상 표적 종양학 포럼 - 2025년 4월 8일, 오후 1시 ET
두 발표 모두 블랙 다이아몬드 테라퓨틱스 웹사이트의 투자자 관계 섹션을 통해 웹캐스트로 접근할 수 있으며, 재생은 90일 동안 가능합니다.
Black Diamond Therapeutics (Nasdaq: BDTX), une entreprise d'oncologie en phase clinique spécialisée dans les thérapies MasterKey pour le traitement du cancer, a annoncé sa prochaine participation à deux grandes conférences pour investisseurs.
Le Président et CEO de l'entreprise, Mark Velleca, M.D., Ph.D., présentera lors des événements suivants :
- 24ème Conférence Virtuelle de Santé de Needham - 7 avril 2025, à 15h00 ET
- Forum Virtuel d'Oncologie Ciblée Stifel 2025 - 8 avril 2025, à 13h00 ET
Les deux présentations seront accessibles par webdiffusion dans la section relations investisseurs du site Web de Black Diamond Therapeutics, avec des rediffusions disponibles pendant 90 jours.
Black Diamond Therapeutics (Nasdaq: BDTX), ein klinisches Onkologieunternehmen, das sich auf MasterKey-Therapien zur Krebsbehandlung spezialisiert hat, hat seine bevorstehende Teilnahme an zwei wichtigen Investorenkonferenzen angekündigt.
Der Präsident und CEO des Unternehmens, Mark Velleca, M.D., Ph.D., wird bei den folgenden Veranstaltungen präsentieren:
- 24. Jährliche Needham Virtuelle Gesundheitskonferenz - 7. April 2025, um 15:00 Uhr ET
- Stifel 2025 Virtuelles Zielonkologieforum - 8. April 2025, um 13:00 Uhr ET
Beide Präsentationen werden über einen Webcast im Bereich Investor Relations der Website von Black Diamond Therapeutics zugänglich sein, mit Wiederholungen, die 90 Tage lang verfügbar sind.
- None.
- None.
CAMBRIDGE, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows:
- 24th Annual Needham Virtual Healthcare Conference presentation at 3:00pm ET on Monday, April 7, 2025
- Stifel 2025 Virtual Targeted Oncology Forum fireside chat at 1:00pm ET on Tuesday, April 8, 2025
Webcasts will be available at the start of the presentations on the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. Replays of the presentations will also be available and archived on the site for 90 days.
About Black Diamond Therapeutics
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. For more information, please visit www.blackdiamondtherapeutics.com.
Contacts
For Investors:
investors@bdtx.com
For Media:
media@bdtx.com
FAQ
When is Black Diamond Therapeutics (BDTX) presenting at the Needham Healthcare Conference 2025?
How long will BDTX's investor conference webcasts be available for replay?
What investor conferences is BDTX participating in during April 2025?
Where can investors access Black Diamond Therapeutics' (BDTX) conference presentations?
What type of cancer therapies is BDTX developing?
